Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Evotec Rises on Boehringer Ingelheim Milestone Payment

Evotec AG rose the most in almost two weeks after saying it received a payment of 1.5 million euros ($1.93 million) for achieving a research milestone under an agreement with Boehringer Ingelheim GmbH.

Evotec increased as much as 5.3 percent to 2.62 euros, the biggest intraday gain since June 25, and was trading 3 percent higher at 1:49 p.m. in Frankfurt, giving the Hamburg-based company a market value of 303.8 million euros.

A pain treatment that Evotec is working on for Boehringer Ingelheim has reached the preclinical development phase, the company said today in a statement. The milestone, reached in June, represents an “important transition,” Chief Operating Officer Mario Polywka said today in a statement.

Evotec has had a drug-discovery alliance with Boehringer Ingelheim since 2004 and has produced 18 milestones so far, it said today. The company has shifted its business focus to very early-stage development, shuttling prospective treatments from academic research to pharmaceutical companies, and drug-development services, away from finding and marketing its own products.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.